Finance

Beta
Senarai
Sektor ekuiti
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Buka
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
BMRN:VIE
Biomarin Pharmaceutical Inc
€46.57
+1.13%
(+0.52) 1H
30 Apr, 5:36:00 PTG GMT+2  ·   EUR
Semua simbol
SimbolPriceChange% Change
Generating top insights for BMRN...
Buka
€46.42
High
€46.62
Low
€46.39
Mkt. cap
10.45B
Avg. vol.
4.00
Volume
0.00
52-wk high
€57.04
52-wk low
€44.02
Shares outstanding
178.06J
No. of employees
3K
News stories
From sources across the web
Profil
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMac 1997
HeadquartersSan Rafael, California, Amerika Syarikat
Sector-
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mac 2025
Jun 2025
Sep 2025
Dis 2025
Revenue
745.14J
825.41J
776.13J
874.56J
Cost of goods sold
310.29J
311.40J
549.56J
348.91J
Cost of revenue
310.29J
311.40J
549.56J
348.91J
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206.12J
232.28J
268.42J
324.16J
Operating expense
210.96J
237.12J
273.26J
329.01J
Total operating expenses
521.25J
548.52J
822.82J
677.92J
Operating income
223.89J
276.89J
-46.69J
196.64J
Other non operating income
-1.95J
4.83J
5.09J
1.02J
EBT including unusual items
238.09J
297.87J
-26.32J
-27.15J
EBT excluding unusual items
238.09J
297.87J
-26.32J
214.10J
Income tax expense
52.40J
57.34J
4.42J
19.42J
Effective tax rate
22.01%
19.25%
-16.79%
-71.52%
Other operating expenses
-
-
-
-
Net income
185.69J
240.53J
-30.74J
-46.57J
Net profit margin
24.92%
29.14%
-3.96%
-5.33%
Earnings per share
1.13
1.44
0.12
0.46
Interest and investment income
19.01J
18.83J
17.85J
19.21J
Interest expense
-2.86J
-2.68J
-2.58J
-2.78J
Net interest expenses
16.15J
16.15J
15.28J
16.43J
Depreciation and amortization charges
-
-
-
-
EBITDA
245.96J
295.45J
-28.20J
209.68J
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

Tugasan saya
Anda belum membuat tugasan lagi
Tugasan anda akan dipaparkan di sini. Jadualkan tugasan dan manfaatkan Google Finance semasa anda tiada.
Templat
Ringkasan senarai amatan
Analisis prapasaran harian bagi senarai amatan anda
Pendapatan Akan Datang
Laporan pendapatan akan datang dalam minggu ini
Kemudahubahan & Jumlah yang Tidak Normal
Amaran awal kemudahubahan dan jumlah hari ini
AI content may include mistakes. Learn more